^
H3.3K27M
|
Glioma
|
H3.3K27M
|
Glioma
|
anlotinib Sensitive: C4 – Case Studies
Acta Neurochir (Wien) - 1 week
|
anlotinib Sensitive: C4 – Case Studies
Acta Neurochir (Wien) - 1 week
|
IDH2 mutation
|
GBM
|
IDH2 mutation
|
GBM
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
IDH1 mutation
|
GBM
|
IDH1 mutation
|
GBM
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
MGMT promoter methylation
|
GBM
|
MGMT promoter methylation
|
GBM
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
AV-GBM-1 Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Brain Cancer
|
No biomarker
|
Brain Cancer
|
lomustine Sensitive: A1 - Approval
|
lomustine Sensitive: A1 - Approval
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
Anaplastic Astrocytoma
|
No biomarker
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: A1 - Approval
|
temozolomide Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
temozolomide Sensitive: A1 - Approval
|
temozolomide Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
carmustine Sensitive: A1 - Approval
|
carmustine Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
teserpaturev Sensitive: A1 - Approval
|
teserpaturev Sensitive: A1 - Approval
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
PCV Sensitive: A2 - Guideline
|
PCV Sensitive: A2 - Guideline
|
No biomarker
|
Anaplastic Astrocytoma
|
No biomarker
|
Anaplastic Astrocytoma
|
PCV Sensitive: A2 - Guideline
|
PCV Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
PCV Sensitive: A2 - Guideline
|
PCV Sensitive: A2 - Guideline
|
MGMT promoter methylation
|
GBM
|
MGMT promoter methylation
|
GBM
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Oligodendroglioma
|
No biomarker
|
Oligodendroglioma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Meningioma
|
No biomarker
|
Meningioma
|
bevacizumab + everolimus Sensitive: A2 - Guideline
|
bevacizumab + everolimus Sensitive: A2 - Guideline
|
No biomarker
|
Meningioma
|
No biomarker
|
Meningioma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Meningioma
|
No biomarker
|
Meningioma
|
sunitinib Sensitive: A2 - Guideline
|
sunitinib Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cisplatin + cyclophosphamide oral + vincristine Sensitive: A2 - Guideline
|
cisplatin + cyclophosphamide oral + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cisplatin + vincristine + lomustine Sensitive: A2 - Guideline
|
cisplatin + vincristine + lomustine Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
trametinib + dabrafenib Sensitive: A2 - Guideline
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline
|
lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
lomustine Sensitive: A2 - Guideline
|
lomustine Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
regorafenib Sensitive: A2 - Guideline
|
regorafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
temozolomide gel Sensitive: A2 - Guideline
|
temozolomide gel Sensitive: A2 - Guideline
|
BRAF V600E
|
Glioma
|
BRAF V600E
|
Glioma
|
selumetinib Sensitive: A2 - Guideline
|
selumetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
cobimetinib Sensitive: A2 - Guideline
|
cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
vemurafenib Sensitive: A2 - Guideline
|
vemurafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Astrocytoma
|
BRAF V600E
|
Astrocytoma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
cobimetinib Sensitive: A2 - Guideline
|
cobimetinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
trametinib Sensitive: A2 - Guideline
|
trametinib Sensitive: A2 - Guideline
|
BRAF V600E
|
Ganglioglioma
|
BRAF V600E
|
Ganglioglioma
|
dabrafenib Sensitive: A2 - Guideline
|
dabrafenib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Glioma
|
NTRK3 fusion
|
Glioma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Glioma
|
NTRK1 fusion
|
Glioma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
lomustine Sensitive: A2 - Guideline
|
lomustine Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Glioma
|
NTRK3 fusion
|
Glioma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Glioma
|
NTRK2 fusion
|
Glioma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Glioma
|
NTRK1 fusion
|
Glioma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
BRAF V600E
|
GBM
|
BRAF V600E
|
GBM
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
vemurafenib + cobimetinib Sensitive: A2 - Guideline
|
BRAF fusion
|
Glioma
|
BRAF fusion
|
Glioma
|
selumetinib Sensitive: A2 - Guideline
|
selumetinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
GBM
|
NTRK3 fusion
|
GBM
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
GBM
|
NTRK1 fusion
|
GBM
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
GBM
|
NTRK3 fusion
|
GBM
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GBM
|
NTRK2 fusion
|
GBM
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
GBM
|
NTRK1 fusion
|
GBM
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
GBM
|
NTRK2 fusion
|
GBM
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
lomustine Sensitive: A2 - Guideline
|
lomustine Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
etoposide IV Sensitive: A2 - Guideline
|
etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cyclophosphamide oral Sensitive: A2 - Guideline
|
cyclophosphamide oral Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
lapatinib Sensitive: A2 - Guideline
|
lapatinib Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
No biomarker
|
Meningioma
|
No biomarker
|
Meningioma
|
DG3173 Sensitive: A2 - Guideline
|
DG3173 Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
vismodegib Sensitive: A2 - Guideline
|
vismodegib Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
cisplatin + etoposide IV Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
etoposide oral Sensitive: A2 - Guideline
|
etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
temozolomide Sensitive: A2 - Guideline
|
temozolomide Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
cyclophosphamide oral + etoposide oral Sensitive: A2 - Guideline
|
cyclophosphamide oral + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
carboplatin + cyclophosphamide oral + etoposide oral Sensitive: A2 - Guideline
|
carboplatin + cyclophosphamide oral + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
VAL-083 Sensitive: B - Late Trials
|
VAL-083 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
enzastaurin Sensitive: B - Late Trials
|
enzastaurin Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
DNX-2401 Sensitive: B - Late Trials
|
DNX-2401 Sensitive: B - Late Trials
|
H3.3K27M
|
Glioma
|
H3.3K27M
|
Glioma
|
ONC201 Sensitive: B - Late Trials
|
ONC201 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
GDC-0084 Sensitive: B - Late Trials
|
GDC-0084 Sensitive: B - Late Trials
|
MGMT unmethylation
|
GBM
|
MGMT unmethylation
|
GBM
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
temozolomide gel Sensitive: B - Late Trials
|
temozolomide gel Sensitive: B - Late Trials
|
IDH1 R132H
|
Anaplastic Astrocytoma
|
IDH1 R132H
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
MGMT promoter methylation
|
Anaplastic Astrocytoma
|
temozolomide Sensitive: B - Late Trials
|
temozolomide Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
temozolomide gel Sensitive: B - Late Trials
|
temozolomide gel Sensitive: B - Late Trials
|
IDH1 mutation
|
Glioma
|
IDH1 mutation
|
Glioma
|
PCV Sensitive: B - Late Trials
|
PCV Sensitive: B - Late Trials
|
IDH2 mutation
|
Glioma
|
IDH2 mutation
|
Glioma
|
PCV Sensitive: B - Late Trials
|
PCV Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
GLR2007 Sensitive: B - Late Trials
|
GLR2007 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
VB-111 Sensitive: B - Late Trials
|
VB-111 Sensitive: B - Late Trials
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
OKN-007 Sensitive: B - Late Trials
|
OKN-007 Sensitive: B - Late Trials
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
CYNK-001 Sensitive: B - Late Trials
|
CYNK-001 Sensitive: B - Late Trials
|
